Respiratory Syncytial Virus (RSV) Vaccine Acceptance Among the Elderly in Al-Qassim Region, Saudi Arabia.

IF 2.6 3区医学 Q2 MEDICINE, GENERAL & INTERNAL

Patient preference and adherence Pub Date : 2026-09-09 eCollection Date: 2026-01-01 DOI:10.2147/PPA.S630028

Moath Aljohani, Dawood Al-Oraini

{"title":"Respiratory Syncytial Virus (RSV) Vaccine Acceptance Among the Elderly in Al-Qassim Region, Saudi Arabia.","authors":"Moath Aljohani, Dawood Al-Oraini","doi":"10.2147/PPA.S630028","DOIUrl":null,"url":null,"abstract":"Objective: The Respiratory Syncytial Virus (RSV) vaccine has recently been introduced in Saudi Arabia for adults aged 60 and older. There are limited published studies on this topic in Saudi Arabia for this age group. This study aimed to assess RSV vaccine acceptance among older adults in the Al-Qassim region of Saudi Arabia.Methods: The data were collected via online forms that invited participants aged 60 years and older, living in the Al-Qassim region, to participate. The study tool included items related to sociodemographic variables, chronic disease history, knowledge of the RSV disease, and perceived susceptibility and severity. In addition to previous RSV uptake and willingness to vaccinate, along with previous vaccination history for other indicated vaccines such as herpes zoster, Influenza, and Pneumococcal.Results: 341 responses met the inclusion criteria. The majority of participants were aged < 70 years (74.5%), males (57.5%), and 38.1% had a university education or higher. 67.7% had at least one chronic disease, with diabetes being the most common (41.8%). The majority (83.6%) have never heard of RSV. Only 5 (1.5%) respondents reported prior uptake, while 16.1% demonstrated RSV acceptance overall. The most prominent facilitator among vaccine-acceptant individuals was physician or healthcare professional recommendation (45.5%). The most cited barriers among vaccine-hesitant or undecided individuals (n=286) were the perception of the RSV vaccine as \"a new vaccine\" (50.0%) and concerns about vaccine safety and effectiveness (44.1% and 26.2%, respectively). Only higher uptake of other indicated vaccines showed a significant association with vaccine acceptance (aOR 1.575, 95% CI 1.220-2.033, p < 0.001).Conclusion: The study demonstrated very low vaccine uptake and willingness, with reported barriers like concerns about the vaccine's recent introduction and uncertainty about its safety and effectiveness. Efforts tailored to educate the elderly about the vaccine's importance, safety, and effectiveness are needed to improve vaccine uptake.","PeriodicalId":19972,"journal":{"name":"Patient preference and adherence","volume":"20 ","pages":"630028"},"PeriodicalIF":2.6000,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13571643/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Patient preference and adherence","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/PPA.S630028","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: The Respiratory Syncytial Virus (RSV) vaccine has recently been introduced in Saudi Arabia for adults aged 60 and older. There are limited published studies on this topic in Saudi Arabia for this age group. This study aimed to assess RSV vaccine acceptance among older adults in the Al-Qassim region of Saudi Arabia.

Methods: The data were collected via online forms that invited participants aged 60 years and older, living in the Al-Qassim region, to participate. The study tool included items related to sociodemographic variables, chronic disease history, knowledge of the RSV disease, and perceived susceptibility and severity. In addition to previous RSV uptake and willingness to vaccinate, along with previous vaccination history for other indicated vaccines such as herpes zoster, Influenza, and Pneumococcal.

Results: 341 responses met the inclusion criteria. The majority of participants were aged < 70 years (74.5%), males (57.5%), and 38.1% had a university education or higher. 67.7% had at least one chronic disease, with diabetes being the most common (41.8%). The majority (83.6%) have never heard of RSV. Only 5 (1.5%) respondents reported prior uptake, while 16.1% demonstrated RSV acceptance overall. The most prominent facilitator among vaccine-acceptant individuals was physician or healthcare professional recommendation (45.5%). The most cited barriers among vaccine-hesitant or undecided individuals (n=286) were the perception of the RSV vaccine as "a new vaccine" (50.0%) and concerns about vaccine safety and effectiveness (44.1% and 26.2%, respectively). Only higher uptake of other indicated vaccines showed a significant association with vaccine acceptance (aOR 1.575, 95% CI 1.220-2.033, p < 0.001).

Conclusion: The study demonstrated very low vaccine uptake and willingness, with reported barriers like concerns about the vaccine's recent introduction and uncertainty about its safety and effectiveness. Efforts tailored to educate the elderly about the vaccine's importance, safety, and effectiveness are needed to improve vaccine uptake.

查看原文本刊更多论文

沙特阿拉伯Al-Qassim地区老年人呼吸道合胞病毒（RSV）疫苗接受情况

目的：呼吸道合胞病毒（RSV）疫苗最近在沙特阿拉伯引入，用于60岁及以上的成年人。沙特阿拉伯针对这一年龄组发表的关于这一主题的研究有限。本研究旨在评估沙特阿拉伯Al-Qassim地区老年人对RSV疫苗的接受程度。方法：通过在线表格收集数据，邀请居住在Al-Qassim地区的60岁及以上的参与者参与。研究工具包括与社会人口学变量、慢性疾病史、对RSV疾病的了解以及感知的易感性和严重程度相关的项目。除了既往的RSV摄取和疫苗接种意愿，以及其他指征疫苗（如带状疱疹、流感和肺炎球菌）的既往疫苗接种史。结果：341例应答符合纳入标准。大多数参与者年龄< 70岁（74.5%），男性（57.5%），38.1%具有大学及以上学历。67.7%的人至少患有一种慢性疾病，其中糖尿病最为常见（41.8%）。大多数人（83.6%）从未听说过呼吸道合胞病毒。只有5名（1.5%）应答者报告先前接受过RSV，而16.1%的应答者总体上表示接受RSV。在接受疫苗的个体中，最突出的促进因素是医生或卫生保健专业人员的建议（45.5%）。在疫苗犹豫或未决定个体（n=286）中，提到最多的障碍是认为RSV疫苗是“一种新疫苗”（50.0%）和对疫苗安全性和有效性的担忧（分别为44.1%和26.2%）。只有较高的其他指征疫苗接种率与疫苗接受度显著相关（aOR 1.575, 95% CI 1.220-2.033, p < 0.001）。结论：该研究表明，疫苗的吸收率和意愿非常低，报告的障碍包括对疫苗最近引入的担忧以及对其安全性和有效性的不确定性。为了提高疫苗的吸收率，需要针对老年人进行疫苗重要性、安全性和有效性的教育。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Patient preference and adherence MEDICINE, GENERAL & INTERNAL-

CiteScore

3.60

自引率

4.50%

发文量

354

审稿时长

6-12 weeks

期刊介绍： Patient Preference and Adherence is an international, peer reviewed, open access journal that focuses on the growing importance of patient preference and adherence throughout the therapeutic continuum. The journal is characterized by the rapid reporting of reviews, original research, modeling and clinical studies across all therapeutic areas. Patient satisfaction, acceptability, quality of life, compliance, persistence and their role in developing new therapeutic modalities and compounds to optimize clinical outcomes for existing disease states are major areas of interest for the journal. As of 1st April 2019, Patient Preference and Adherence will no longer consider meta-analyses for publication.